ProSomnus Contributes Two Scientific Abstracts Accepted for Presentation at the 2024 American Academy of Dental Sleep Medicine Annual Meeting

PLEASANTON, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy, announced that it has contributed two scientific abstracts that have been accepted for presentation at the 2024 American Academy of Dental Sleep Medicine Meeting in New Orleans.

• Abstract #019
  “Assessing Health Outcomes When Treating Obstructive Sleep Apnea with Mandibular Protruding Appliances”
  Erin Mosca, PhD¹; Joshua Grosse, MMath¹; John Remmers, MD^{1
  1}ProSomnus Sleep Technologies, Pleasanton, CA

Data from three prospective clinical studies with a pooled sample size of 134 were analyzed to assess the relationship between apnea-hypopnea index (AHI), a frequency-based metric, and sleep apnea-specific hypoxic burden (SASHB), a metric that captures the risk associated with obstructive sleep apnea (OSA). Precision oral appliance therapy significantly reduced AHI and SASHB in all severities of OSA. 76% of study participants achieved therapeutic success when it was defined as AHI < 10/h, whereas 94% achieved therapeutic success when it was defined as SASHB < 60% min/h. AHI appears to misclassify some individuals as therapeutic failures to precision oral appliance therapy despite their having an SAHSB below the threshold of increased risk; therefore, SASHB likely provides a more meaningful assessment of OSA treatment response than AHI as it accounts for the risk associated with the disease.

“The research indicates that judging outcome using sleep apnea-specific hypoxic burden reveals that the traditional methods are inappropriately restrictive,” commented Dr. John E. Remmers, MD, Chief Scientist for ProSomnus Sleep Technologies. “Efficacy of oral appliance therapy is higher than that previously understood when a predictor of long-term clinical outcome is used.”

• Abstract #032
  “Medical Grade Class VI Devices Demonstrate Statistically Significantly Lower Mean Staining than Other Devices Tested”
  Len Liptak, MBA¹, Mark Murphy, DDS^1,2, ABDSM, Sung Kim^{1
  1}ProSomnus Sleep Technologies, Pleasanton, CA, ²Funktional Sleep, Rochester, MI

Data from this investigation evaluates the staining profile of seven sleep apnea devices. Various, previous, independent studies establish material staining as a surrogate for bacteria colonization and health risk. Devices made from medical grade class VI material (ProSomnus EVO and ProSomnus EVO [PH]) demonstrated statistically significantly lower staining than the four other oral devices tested and were the only two devices in the study to exhibit less staining than a CPAP mask.